VANCOUVER, BC–(Marketwired – November 06, 2016) – BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced its team is attending BIO Europe, November 7th to 9th, in Cologne, Germany. In addition, the company announced that Dr. Paul Lockman’s recently published paper on biOasis’s Transcend technology linked to Trastuzumab has been honored by being featured on the cover of the December issue of Pharmaceutical Research, Volume 33, Issue 12.
“BIO Europe is Europe’s largest partnering conference for the global biotechnology industry,” commented Rob Hutchison, biOasis’s CEO. “The conference attracts leading dealmakers from biotech, pharma and finance. We have chosen to attend BIO Europe because it enables us to meet with many potential partners and companies investigating the licensing of our Transcend technology. Our team has prepared for confirmed meetings with over 40 companies during the three days of the conference.”
The Lockman paper, entitled, “Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study,” was published in Pharmaceutical Research, an official Journal of the American Association of Pharmaceutical Scientists. The peer-reviewed scientific paper details the results of an in-vivo study of the treatment of Metastatic HER2+ Breast Cancer brain tumors in an animal model using BT2111, biOasis’s Trastuzumab-Melanotransferrin (Transcend) Conjugate.
“Since being first published on-line on August 15th 2016, the Lockman paper on biOasis’s Transcend technology linked to Trastuzumab (sold by Roche under the name Herceptin®) has received significant interest from the industry,” commented Rob Hutchison. “This interest has pushed our development of this program ahead dramatically. We are very pleased to see the team’s hard work and exciting results, all culminating in a great paper, being featured on the cover of the December issue of Pharmaceutical Research.”
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI”. For more information about the company please visit www.bioasis.ca.
Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.
On Behalf of the Board of Directors
Rob Hutchison, Chair CEO
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”